Inflammatory Bowel Disease News

In this video, Uma Mahadevan, MD, director of the Colitis and Crohn’s Disease Center at the University of California, San Francisco, spoke with Healio about a consensus conference on the management of IBD in pregnancy.

In this Healio video, Uma Mahadevan, MD, director of the Colitis and Crohn’s Disease Center at the University of California, San Francisco, discusses new study results assessing the use of interleukin-23 inhibitors in ulcerative colitis.

WASHINGTON — A maintenance dose of subcutaneous Skyrizi may still induce clinical response in patients with ulcerative colitis who failed to achieve response after 12 weeks of IV induction, noted a presenter at Digestive Disease Week.

WASHINGTON — In patients with active Crohn’s disease, guselkumab was superior to both placebo and standard-of-care ustekinumab after 48 weeks of treatment, according to late-breaking data from the phase 3 GALAXI program.

In this Healio video, Uma Mahadevan, MD, director of the Colitis and Crohn’s Disease Center at the University of California, San Francisco, recaps results from the SEQUENCE trial, which were presented at Digestive Disease Week 2024.

Patients with atherosclerosis and elevated LDL plus autoimmune or inflammatory disease may derive particular CV benefit from PCSK9 inhibition with evolocumab, a speaker reported.

WASHINGTON — In this video, Mark Genovese, MD, discusses results of the VIVID-1 study, in which mirikizumab demonstrated noninferiority to ustekinumab for week 52 clinical remission among patients with moderate to severe Crohn’s disease.

WASHINGTON — Patients with Crohn’s disease who ate a catered low-fat, high-fiber diet for 8 weeks experienced improvements in symptoms, inflammation and quality of life vs. those offered counseling alone, researchers reported.

WASHINGTON — Maintenance Skyrizi 180 mg and 360 mg was superior to placebo in achieving clinical remission among patients with moderately to severely active ulcerative colitis who responded to 12-week induction therapy, according to data.

WASHINGTON — Entyvio is “safe and effective” for maintaining sustained steroid-free remission at 1 year in children with inflammatory bowel disease, more so in those with ulcerative colitis vs. Crohn’s disease, according to a researcher.